Download Files:
Clevidipine
$42 – $317
Products Details
Product Description
– Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ).
Web ID
– HY-17436
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C21H23Cl2NO6
References
– [1]Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes.|[2]Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4.|[3]Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37.|[4]Ericsson H, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999 May;27(5):558-64.|[5]Schwieler JH, et al. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999 Aug;34(2):268-74.
CAS Number
– 167221-71-8
Molecular Weight
– 456.32
Compound Purity
– 99.88
SMILES
– O=C(C1=C(C)NC(C)=C(C(OCOC(CCC)=O)=O)C1C2=CC=CC(Cl)=C2Cl)OC
Clinical Information
– Launched
Research Area
– Cardiovascular Disease; Cancer
Solubility
– DMSO : ≥ 50 mg/mL
Target
– Calcium Channel
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
